Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan

References

• JuttnerCAToLBHaylockDNAutologous blood stem cell transplantationTransplant Proc1989211 Pt 3292929312565063
   PubMed Web of Science ®Google Scholar
• HaasRHoADBredthauerUSuccessful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factorExp Hematol199018294981968009
   PubMed Web of Science ®Google Scholar
• EliasADAyashLAndersonKCMobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification in breast cancerBlood19927911303630441350229
   PubMed Web of Science ®Google Scholar
• BruggerWBrossKJFrischMobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatinBlood1992795119312001371415
   PubMed Web of Science ®Google Scholar
• SheridanWPBegleyCGJuttnerCAEffect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapyLancet199233987946406441371817
   PubMed Web of Science ®Google Scholar
• TeplerICannistraSAFreiE3rdUse of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapyJ Clin Oncol1993118158315918101563
   PubMed Web of Science ®Google Scholar
• MellstedtHNiederwieserDLudwigHThe challenge of biosimilarsAnn Oncol200819341141917872902
   PubMed Web of Science ®Google Scholar
• SörgelFLerchHLauberTPhysicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference productBioDrugs201024634735720873878
   PubMed Web of Science ®Google Scholar
• NiederwieserDSchmitzSBiosimilar agents in oncology/haematology: from approval to practiceEur J Haematol201186427728821175852
   PubMed Web of Science ®Google Scholar
• GasconPPresently available biosimilars in hematology-oncology: G-CSFTarget Oncol20127Suppl 1S293422258705
   PubMed Web of Science ®Google Scholar
• AndreolaGBabicARabascioCNegriMMartinelliGLaszloDPlerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantationEur J Haematol201288215415821992403
   PubMed Web of Science ®Google Scholar
• LefrèreFBrignierACElieCFirst experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factorAdv Ther201128430431021400232
   PubMed Web of Science ®Google Scholar
• SivginSKarakusEKaynarLThe comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from TurkeyTransfus Apher Sci201348331532023611684
   PubMed Web of Science ®Google Scholar
• PublicoverARichardsonDSDaviesAUse of biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftmentBr J Haematol2013162110711123614650
   PubMed Web of Science ®Google Scholar
• SchmittMXuXHilgendorfIMobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donorsBone Marrow Transplant201348792292523318540
   PubMed Web of Science ®Google Scholar
• MankoJWalter-CroneckaAJawniakDA clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilizationPharmacol Rep201466223924224911076
   PubMed Web of Science ®Google Scholar
• SchmittMPublicoverAOrchardKHBiosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantationTheranostics20144328028924505236
   PubMed Web of Science ®Google Scholar
• CesaroSTridelloGPreteABiosimilar granulocyte colony-stimulating factor for mobilization of autologous peripheral blood stem cell in pediatric hematology-oncology patientsTransfusion201555224625225070657
   PubMed Web of Science ®Google Scholar
• BassiSStroppaEMMoroniCFSafety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with fifferent conditioning regimensBlood Transfus201513347848325761321
   PubMed Web of Science ®Google Scholar
• PhamTPatilSFlemingSComparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantationTransfusion201555112709271326173921
   PubMed Web of Science ®Google Scholar
• MarchesiFVaccaMGumenyukSBiosimilar filgrastim (Zarzio®) vs. lenograstim (Myelostim®) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experienceLeuk Lymphoma2016571–4489492
   Web of Science ®Google Scholar
• KatsuraKNomuraSXieGLPlatelet procoagulant activity during peripheral blood stem cell harvestClin Appl Thromb Hemost19973124128
   Web of Science ®Google Scholar
• NomuraSInamiNKanazawaSIwasakaTFukuharaSElevation of platelet activation markers and chemokines during peripheral blood stem cell harvest with G-CSFStem Cells200422569670315342934
   PubMed Web of Science ®Google Scholar
• BenderJGUnverzagtKWalkerDGuidelines for determination of CD34+ cells by flow cytometry: application to the harvesting and transplantation of peripheral blood stem cellsWunderESovalatHHenonPHematopoietic Stem Cells: The Mulhouse ManualDayton, OHAlphaMed Press19943143
   Google Scholar
• MercolinoTJConnellyMCMeyerEJImmunologic differentiation of absolute lymphocyte count with an integrated flow cytometric system: a new concept for absolute T cell subset determinationsCytometry19952248597587734
   PubMedGoogle Scholar
• AaproMSCameronDAPettengellREORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumoursEur J Cancer200642152433245316750358
   PubMed Web of Science ®Google Scholar
• SmithTJKhatcheressianJLymanGH2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guidelineJ Clin Oncol200624193187320516682719
   PubMed Web of Science ®Google Scholar
• del GiglioAEniuAGanea-MotanDTopuzovELubenauHXM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapyBMC Cancer2008833219014494
   PubMed Web of Science ®Google Scholar
• EngeltAGriskeviciusLZyuzginYLubenauHdel GiglioAXM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapyLeuk Lymphoma200950337437919347726
   PubMed Web of Science ®Google Scholar
• GatzemeierUCiuleanuTDediuMGanea-MotanELubenauHDel GiglioAXM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapyJ Thorac Oncol2009473674019404210
   PubMed Web of Science ®Google Scholar
• LubenauHBiasPMalyAKPharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trialBioDrugs2009231435119344191
   PubMed Web of Science ®Google Scholar
• FerroHHJuniMBelloRVidalADiezRAPavlovskySUtilization study of filgrastim (Neutromax) during autologous haematopoietic precursor transplantation for myeloma and lymphoma patientsTransfus Apher Sci2009412879319699152
   PubMed Web of Science ®Google Scholar
• ShawBE1ConferDLHwangWYPamphilonDHPulsipherMAConcerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor AssociationHaematologica201196794294721719883
   PubMed Web of Science ®Google Scholar